Hyperkalemia
Treatment Market, by Drug Type (IV Calcium, Insulin, Sodium Bicarbonate,
Beta2 Agonist, Diuretics, Sodium Polystyrene Sulfonate, Others), by Route of
Administration (Oral and Intravenous, Inhalation, Rectal), by Distribution
Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Geography
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) –
Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Hyperkalemia is a diseases in which levels of potassium are higher
than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible
for managing potassium balance in the body by regulating its excretion as well
as its intake. A person is prone to develop hyperkalemia when the consumption
of potassium exceeds that of kidneys’ potential to excrete it. The right amount
of potassium and sodium in the body play a vital role in normal functioning of
the myocardium.
Hyperkalemia can occur due to congestive heart failure,
chronic kidney disease, or diabetic kidney disease. The condition can also
occur when a patient receives renin-angiotensin-aldosterone system inhibitors
(RAAS) in kidney disease. Abnormal levels of potassium can lead to irregular
heartbeats, which can be fatal. Hyperkalemia is diagnosed by kidney functioning
test, creatinine blood test, blood tests, and glucose monitoring.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2406
Hyperkalemia Treatment Market– Dynamics
Increase in prevalence of cardiac arrhythmias and chronic
kidney disease are major factors driving growth of hyperkalemia treatment
market during the forecast period. According to Centers for Disease Control and
Prevention (CDC) report, in 2017 around 30 million or 15% people suffer from
chronic kidney diseases in the U.S. Increasing number of people suffering from
lifestyle-associated diseases also leads to high prevalence of hyperkalemia,
which in turn boost growth of the market.
Hyperkalemia Treatment Market – Regional Insights
On the basis of geography, the global hyperkalemia treatment
market is segmented into North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa. North America is expected to hold dominant position in
the global hyperkalemia treatment market followed by Europe during the forecast
period.
The U.S. holds a dominant position in North America market
due to development in healthcare infrastructure, and Unhealthy lifestyle of U.S
of citizen. As incidence of hyperkalemia has been reported anywhere from 2.6%
to 3.2% which is highest among others region.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/hyperkalemia-treatment-market-2406
Furthermore, Asia Pacific hyperkalemia treatment market is
expected to witness significant growth due increasing launches of drugs for the
treatment of hyperkalemia. For instance, In May 2018, The U.S. Food and Drug
Administration (U.S FDA) approved AstraZeneca’s, Lokelma a drug that is
insoluble, non-absorbed sodium zirconium silicate, oral suspension and acts as
a highly-selective potassium-removing agent for the treatment of hyperkalemia
in adults.
Similarly, in October 2015, the U.S FDA approved Relypsa,
Inc.’s., Veltassa a drug to treat hyperkalemia.
Hyperkalemia Treatment Market - Competitive Landscape
Major players operating in the hyperkalemia treatment market
include, AstraZeneca, Klarvoyant Biogenics Pvt. Ltd, Concordia Pharmaceuticals
Inc, Steadfast MediShield Pvt. Ltd, Perrigo Company plc, AdvaCare Pharma, Eli
Lilly and Company, Carolina Medical Products, Relypsa, Inc., RSM Kilitch Pharma
Pvt. Ltd, Novel Laboratories, and others.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2406
About Coherent
Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
No comments:
Post a Comment